|Manufacturer||Natco Pharma, India|
|Pack Size||Qty||Price Per Pill or Unit||Price||Cart|
|30 Tablet/s||US$ 7.60||US$ 228.13|
Erlonat 150 mg is a cancer medicine containing Erlotinib, which falls into the category of drugs known as EGFR inhibitors. The medication blocks the action of EGFR’s that can be found on the surface of some tumour cells. As a result of this blockage, the cancer cells no longer receive the message needed for growth and spreading of the disease. Erlotinib helps to stop cancer from growing, progressing, and spreading through the body. Erlonat tablets is a prescription medicine for non-small cell lung cancer (NSCLC) of advanced stage. Anti-cancer therapy is also effective in patients with pancreatic cancer.
Pregnant ladies should not use Erlonat 150 mg. This anti-cancer medication may harm the fetus of a pregnant woman who uses this medication. Erlotinib may restrict the growth of the fetus, may develop lung abnormalities, and the women have an increased risk of miscarriage. Use adequate contraception during the treatment and for two months after finishing the course. If you become pregnant, while you are being treated with Erlonat tablets, immediately inform your physician who will decide if the anti-cancer should be discontinued. For breastfeeding mothers, it can be dangerous to receive targeted therapy drugs like Erlotinib because they tend to interfere with the normal division of cells in the body.
Many medications may interact with Erlonat and may affect the way it works; therefore, it is essential to tell your physician about all the medicines, including over the counter medicines, or herbal products. Medications that may affect the working mechanism of Erlonat include ketoconazole, nefazodone, voriconazole, erythromycin, omeprazole, Ranitidine, non-steroidal anti-inflammatory drugs (NSAIDs).
Special care needs to be taken while using cancer drugs under certain conditions. Notify your physician if you have gastrointestinal problems, eye problems, headache, loss of appetite, weight loss, diarrhoea, breathing difficulties and skin disorders.
The recommended dose of Erlonat depends on the condition being treated. The dose varies in patients with lung cancer and pancreatic cancer. It must be taken under the supervision of a physician. If you take more tablets than your physician has prescribed, you should contact your physician, even if you don’t experience any signs of illness. Swallow the tablet with a glass of water. Do not chew or crush the tablet. Consume the medicine n an empty stomach or take one or two hours after eating food. Administering with food may increase the risk of side effects. Be sure to check the expiry date of your anticancer medication and do not use it if the package is already opened or damaged.